After H.C. Wainwright and Cowen & Co. gave Cytosorbents Corp (NASDAQ: CTSO) a Buy rating last month, the company received another Buy, this time from Maxim Group. Analyst Jason McCarthy maintained a Buy rating on Cytosorbents Corp today and set a price target of $18. The company’s shares opened today at $11.
McCarthy observed:
“We note a case study from Mount Sinai suggesting potential for CytoSorb use in hemophagocytic lymphohistiocytosis (HLH), and correspondingly cytokine release syndrome (CRS).”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 11.0% and a 41.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cytosorbents Corp with a $16.13 average price target, which is a 46.6% upside from current levels. In a report issued on August 3, H.C. Wainwright also reiterated a Buy rating on the stock with a $15 price target.
.
See today’s analyst top recommended stocks >>
Based on Cytosorbents Corp’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $5.82 million. In comparison, last year the company had a GAAP net loss of $1.12 million.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CTSO in relation to earlier this year. Most recently, in June 2018, Phillip Chan, the President & CEO of CTSO bought 8,000 shares for a total of $30,000.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CytoSorbents Corp. engages in the development of blood purification technology for the reduction of deadly uncontrolled inflammation in hospitalized patients. Its product, CytoSorb, is a extracorporeal cytokine filter and seeks to reduce cytokine storm that could otherwise cause massive inflammation, organ failure, and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.
